A Study to Evaluate the Efficacy of Rosiglitazone (BRL-049653) on Reduction of Microalbuminuria in Subjects With Type 2 Diabetes Mellitus.
Latest Information Update: 26 Jun 2023
At a glance
- Drugs Rosiglitazone (Primary) ; Glibenclamide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 14 Oct 2008 Status changed from active, no longer recruiting to completed.
- 14 Oct 2008 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
- 14 Aug 2007 New trial record.